The Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia

Trial Profile

The Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Febuxostat (Primary)
  • Indications Angina pectoris; Hyperuricaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2017 Status changed from not yet recruiting to discontinued as Entry were insufficient as expected.
    • 06 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top